Guggenheim Raises Rapport Therapeutics Price Target to $70

Guggenheim has raised its price target for Rapport Therapeutics (RAPP) shares to $70.00, up from $65.00. This increase is based on an updated valuation of the biopharmaceutical company, which specializes in developing small molecule medicines for central nervous system disorders using its proprietary receptor-associated protein platform.